ReviewLeukemia & lymphoma2009
Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.
Review in Leukemia & lymphoma, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 61 citations in OpenAlex.
- PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.BMC cancer · 2018Trial
- Combined therapy in untreated patients improves outcome in nasal NK/T lymphoma: results of a clinical trial.Medical oncology (Northwood, London, England) · 2013Trial
- Types of T-cell lymphoma-a cytogenetic perspective.Annals of medicine and surgery (2012) · 2022Article
- Rhino-Orbital-Cerebral Mycosis and Extranodal Natural Killer or/and T-Cell Lymphoma, Nasal Type.Frontiers in medicine · 2022Article
- Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia.International journal of hematology · 2021Article
- Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia.The Lancet regional health. Western Pacific · 2021Article
- Article
- Case Report:Frontiers in medicine · 2021Article
- Article
- Primary Gastrointestinal Involvement in a Case of Extranodal-Extranasal Natural Killer T Cell Lymphoma.Tanaffos · 2020Article
- Specific Soft-Tissue Invasion and LMP1 Expression Are Potential Indicators of Extranodal NK/T Cell Lymphoma, Nasal Type.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Primary pulmonary extranodal NK/T-cell lymphoma of nasal type misdiagnosed as pneumonia: A case report and literature review.Medicine · 2017Review
- Hemoglobin level, a prognostic factor for nasal extranodal natural killer/T-cell lymphoma patients from stage I to IV: A validated prognostic nomogram.Scientific reports · 2017Article
- Article
- Orphan diseases of the nose and paranasal sinuses: Pathogenesis - clinic - therapy.GMS current topics in otorhinolaryngology, head and neck surgery · 2015Review
- Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on ¹⁸F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma.European journal of nuclear medicine and molecular imaging · 2013Article
- Aggressive mature natural killer cell neoplasms: from epidemiology to diagnosis.Orphanet journal of rare diseases · 2013Review
- Reconstruction of a rare palate defect originating from extranodal natural killer/t-cell lymphoma.Archives of plastic surgery · 2013Article
- LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL).Diagnostic pathology · 2012Article
- Mucor irregularis infection and lethal midline granuloma: a case report and review of published literature.Mycopathologia · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Natural killer/T-cell (NK/T) lymphomas represent a group of rare tumors of NK and NK-T cells. The World Health Organization classifies NK-cell tumors into three types, extranodal NK/T-cell lymphomas (ENKL, nasal and non-nasal), NK-cell leukemias, and a blastic variant (CD4-positive, CD56-positive hematodermic neoplasms). We focus our review to the current concepts in biology and treatment of ENKL. Though considerable advances have been made in our understanding of NK-cell biology, malignant transformation including the role of Epstein-Barr virus, and prognosis, the rare nature of ENKL and its heterogeneity limit the ability to standardize therapy. Radiotherapy is fundamental to treatment of early-stage disease with a role for chemoradiotherapy among high-risk patients. The clinical course of advanced disease is highly aggressive with frequent chemotherapy resistance and a poor prognosis. Therapeutic approaches to advanced-stage or relapsed and refractory disease, including the appropriate sequence of chemotherapy, combined modality therapy, and stem cell transplantation is not well-established. International and multicenter clinical trials are needed for this rare and aggressive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.